Short‐course therapy with imiquimod 5% cream for solar keratoses: A randomized controlled trial

Publisher Website
Google Scholar
Abstract
A dual‐centre, randomized, double‐blind, vehicle‐controlled study was conducted to evaluate the safety and efficacy of short courses of therapy with imiquimod 5% cream in clearing ≥75% of baseline solar keratoses (SK) within a field of treatment. Subjects with 5–15 baseline SK within one treatment area (scalp, forehead and temples, or both cheeks) were randomized to apply imiquimod or vehicle cream to the entire treatment area three times a week for 3 weeks. Subjects were assessed 4 weeks after completing the first course for clearance of lesions. Subjects with P = 0.027). Imiquimod was well tolerated. The present study has a short follow‐up endpoint, but suggests that imiquimod is a potential therapeutic alternative in patients with SK.